西妥昔单克隆抗体联合XELOX化疗治疗老年晚期直肠癌的近远(1)
[摘要] 目的 探讨西妥昔单克隆抗体联合XELOX化疗治疗老年晚期直肠癌的近远期效果及其对血清细胞间黏附分子-1(ICAM-1)、环氧酶-2(Cox-2)和细胞角蛋白-20(CK-20)表达的影响。 方法 选取2009年6月～2013年11月右江民族医学院附属医院肛肠外科收治的88例老年晚期直肠癌患者，根据治疗方案的不同分为XELOX化疗组(单独组)和XELOX化疗+西妥昔单克隆抗体组(联合组)，每组各44例；分别比较两组患者的近远期临床疗效、ICAM-1、Cox-2和CK-20的变化。 结果 联合组的治疗有效率为70.45%，显著高于单独组的40.91%(P < 0.05)，但两组患者疾病控制率和不良反应发生率比较差异无统计学意义(P > 0.05)；联合组1年生存率与单独组比较，差异无统计学意义(P > 0.05)；联合组2年生存率明显高于单独组(P < 0.05)；而且，联合组患者的局部复发与转移率也明显低于单独组(P < 0.05)；单独组患者的平均生存时间为16.263个月，显著短于联合组的20.658个月(P < 0.05)；治疗后两组患者ICAM-1、Cox-2和CK-20表达水平均显著降低(P < 0.05)；而且，联合组患者的改善程度明显优于单独组，差异有统计学意义(P < 0.05)。 结论 西妥昔单克隆抗体联合XELOX化疗可显著提高老年晚期直肠癌的近远期临床疗效，抑制肿瘤相关基因ICAM-1、Cox-2和CK-20的水平。
[关键词] 直肠癌；西妥昔单克隆抗体；XELOX化疗；细胞间黏附分子-1；环氧酶-2；细胞角蛋白-20
[中图分类号] R979.1 [文献标识码] A [文章编号] 1673-7210(2016)03(b)-0100-04
[Abstract] Objective To investigate short and long term clinical effects of Cetuximab and XELOX chemotherapy in the treatment of advanced rectal cancer and their influence on intercellular adhesion molecular-1 (ICAM-1)， cyclo-oxygenase-2 (Cox-2) and CK-20 (eytokertin-20). Methods From June 2009 to November 2013， in Department of Anus & Intestine Surgery， Affiliated Hospital of Youjiang Medical University for Nationalities， 88 elderly patients with advanced rectal cancer were selected and divided into XELOX chemotherapy group (single group) and XELOX chemotherapy plus Cetuximab group (combined group) according to the treatment， with 44 cases in each group. Short and long term clinical effects were compared between two groups， and the levels of ICAM-1， Cox-2 and CK-20 in two groups were compared. Results The clinical effective rate of combined group was 70.45%， which was significantly higher than that of single group (40.91%) (P < 0.05)； there were no significant differences of the disease control rate and adverse reaction rate between two groups (P > 0.05)； the 1 year survival rate of combined group was compared with the single group， the difference was not statistically significant (P > 0.05)； but the 2 years survival rate of the combined group was longer than that of single group (P < 0.05)； the local recurrence rate and metastasis rate of combined group were significantly lower than those of single group (P < 0.05)； the average survival time of the single group was 16.263 months， which was significantly shorter than that of the combined group (20.658 months) (P < 0.05)； the levels of CK-20， Cox-2 and ICAM-1 significantly decreased in the two groups after treatment (P < 0.05)， and the improvement of the combined group was significantly better than that of the single group (P < 0.05). Conclusion The combination of Cetuximab and XELOX chemotherapy can significantly improve the clinical efficacy of elderly patients with advanced rectal cancer， and inhibit the levels of tumor related genes ICAM-1， Cox-2 and CK-20., 百拇医药(黄展易 杨昌谋 郭俊宇)
[关键词] 直肠癌；西妥昔单克隆抗体；XELOX化疗；细胞间黏附分子-1；环氧酶-2；细胞角蛋白-20
[中图分类号] R979.1 [文献标识码] A [文章编号] 1673-7210(2016)03(b)-0100-04
[Abstract] Objective To investigate short and long term clinical effects of Cetuximab and XELOX chemotherapy in the treatment of advanced rectal cancer and their influence on intercellular adhesion molecular-1 (ICAM-1)， cyclo-oxygenase-2 (Cox-2) and CK-20 (eytokertin-20). Methods From June 2009 to November 2013， in Department of Anus & Intestine Surgery， Affiliated Hospital of Youjiang Medical University for Nationalities， 88 elderly patients with advanced rectal cancer were selected and divided into XELOX chemotherapy group (single group) and XELOX chemotherapy plus Cetuximab group (combined group) according to the treatment， with 44 cases in each group. Short and long term clinical effects were compared between two groups， and the levels of ICAM-1， Cox-2 and CK-20 in two groups were compared. Results The clinical effective rate of combined group was 70.45%， which was significantly higher than that of single group (40.91%) (P < 0.05)； there were no significant differences of the disease control rate and adverse reaction rate between two groups (P > 0.05)； the 1 year survival rate of combined group was compared with the single group， the difference was not statistically significant (P > 0.05)； but the 2 years survival rate of the combined group was longer than that of single group (P < 0.05)； the local recurrence rate and metastasis rate of combined group were significantly lower than those of single group (P < 0.05)； the average survival time of the single group was 16.263 months， which was significantly shorter than that of the combined group (20.658 months) (P < 0.05)； the levels of CK-20， Cox-2 and ICAM-1 significantly decreased in the two groups after treatment (P < 0.05)， and the improvement of the combined group was significantly better than that of the single group (P < 0.05). Conclusion The combination of Cetuximab and XELOX chemotherapy can significantly improve the clinical efficacy of elderly patients with advanced rectal cancer， and inhibit the levels of tumor related genes ICAM-1， Cox-2 and CK-20., 百拇医药(黄展易 杨昌谋 郭俊宇)